Raymond James reiterates outperform rating for Progressive stock

Raymond James reiterated its Outperform rating for Progressive (PGR) with a $305 price target, citing the company's ability to maintain a favorable combined ratio and achieve industry-leading return on equity by 2027. Progressive reported strong April 2025 results, including an 11% increase in Net Premiums Written and a consolidated combined ratio improvement to 84.9%, driving a 134% increase in net income to $986 million. While Q1 2025 revenue exceeded expectations, EPS fell short, and Keefe, Bruyette & Woods maintained a Market Perform rating, noting potential short-term challenges related to core loss ratios and policy growth.

Analysis

Raymond James has reiterated an Outperform rating on Progressive Corp. (PGR) with a $305.00 price target, underscoring confidence in the company's capacity to sustain a favorable combined ratio over the next two years, potentially achieving industry-leading return on equity by 2027. This optimism is supported by 13 upward analyst earnings revisions and a "GREAT" financial health score of 3.56 out of 5 from InvestingPro. Progressive's stock has appreciated approximately 1% since reporting April 2025 results that surpassed analyst expectations, and it currently trades near its 52-week high of $292.99, marking a 38% return over the past year. Operationally, April 2025 saw a 17% year-over-year increase in consolidated policies in force (PIF), driven by a 23% rise in direct auto PIF and an 18% increase in agency auto PIF. Net Premiums Written (NPW) for April 2025 grew 11% year-over-year, a significant acceleration from the 2% increase in April 2024, with personal lines Direct NPW and Agency NPW up 20% and 18% respectively. Analysts project a 13% consolidated NPW growth for Q2 2025, and overall LTM revenue growth stands at 20.74%. Profitability metrics have also shown considerable strength: the consolidated combined ratio improved to 84.9% in April 2025 from 89.0% a year prior, and the underlying combined ratio improved to 83.6% from 85.0%. The company reported $118 million in favorable prior year development for April 2025, a stark contrast to the $14 million adverse development in April 2024. Net investment income surged 29% year-over-year to $281 million. Consequently, net income for April 2025 more than doubled to $986 million, a 134% increase, with EPS climbing to $1.68 from $0.72. However, Q1 2025 results were mixed, with revenue of $22.21 billion exceeding forecasts, but EPS of $4.37 falling short of the anticipated $4.74. Corporate actions include a renewed share repurchase authorization for up to 25 million common shares and a quarterly dividend of $0.10 per share. Keefe, Bruyette & Woods offers a more cautious view, maintaining a Market Perform rating despite upward EPS revisions for 2025 and 2026, citing potential short-term challenges related to core loss ratios and policy growth.

Key Decisions for Investors

• Investors should consider the strong operational momentum evidenced by significant growth in policies in force, net premiums written, and a markedly improved combined ratio, which aligns with Raymond James's bullish outlook and $305 price target.
• It is advisable to monitor upcoming financial reports for sustained policy growth and the trajectory of core loss ratios, especially in light of Keefe, Bruyette & Woods' cautionary note on potential short-term challenges, despite their upward EPS revisions.
• Given the stock is trading near its 52-week high after a substantial annual gain, investors should evaluate the current valuation against the robust growth metrics and the board's confidence signaled by the share repurchase program, weighing potential upside against the risk of a near-term consolidation.